Just as CTLA4 antagonists alone can only restore PD-1+CTLA-4+ TILs response to tumor antigens, but not CTLA4- TILs (40), single immune checkpoint blockade targets a limited subset of CD8+T cells, while dual or multiple immunotherapies lead to progressively better outcomes. This evidence concerns the gene CTLA4 and neoplasm.